Scientists consider fungal infection vax from yeast; The vaccination-tracking nightmare;

Vaccine Research

Scientists found that mice injected with baker's yeast could survive high doses of aspergillosis, a fungal infection that causes kidney and liver failure in patients with weak immune systems by attacking their lungs. The mice received three doses a week apart of the yeast, and could be used to develop a vaccine against fungal infections. News

Vaccine Market

While Inovio posted a $2.8 million net loss for the second quarter, its revenues more than doubled, rising to $2.4 million from $1.1 million in Q2 2010. Report

The Federal Commission for the Protection Against Sanitary Risk for the Mexico Ministry of Health has awarded the GMP certificate to Sinovac for its seasonal flu vaccine and hepatitis A vaccine. Sinovac release

Cumberland County, NC, health officials have vaccinated nearly 2,000 individuals who may have been exposed to hepatitis A at a local Olive Garden. So far, only the infected employee has been ill. Item

Emergent BioSolutions announced it had a profit of $14.2 million during the second quarter, thanks mostly to sales of its BioThrax anthrax vaccine. The company's total revenue hit $71.5 million, a 28% increase from the year previous. Report

And Finally... M. Katie Charles, a graduate student at Johns Hopkins' Bloomberg School of Public Health, wrote a piece for the Huffington Post on the difficulties of tracking vaccinations, both by the individual and physicians. More

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.